Option Care Health (NASDAQ:OPCH) Issues Quarterly Earnings Results

Option Care Health (NASDAQ:OPCH) posted its quarterly earnings data on Wednesday. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.03, Briefing.com reports. The firm had revenue of $1.23 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Option Care Health had a return on equity of 14.77% and a net margin of 4.60%. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 EPS. Option Care Health updated its FY 2024 guidance to EPS.

Option Care Health Stock Performance

NASDAQ:OPCH opened at $31.61 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.39 and a current ratio of 1.77. Option Care Health has a fifty-two week low of $26.11 and a fifty-two week high of $35.74. The firm has a market cap of $5.49 billion, a PE ratio of 20.80, a price-to-earnings-growth ratio of 1.43 and a beta of 1.24. The business has a 50 day moving average price of $29.10 and a 200-day moving average price of $30.69.

Analysts Set New Price Targets

A number of research analysts have commented on OPCH shares. Barrington Research increased their price target on shares of Option Care Health from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday. JMP Securities started coverage on shares of Option Care Health in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $36.00 target price on the stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.